已发表论文

溶血磷脂酰胆碱(17:0)改善 HFD 诱导的高血糖和胰岛素抵抗:一项机械小鼠模型研究

 

Authors Bao L, Zhang Y, Yan S, Yan D, Jiang D

Received 29 April 2022

Accepted for publication 5 September 2022

Published 15 November 2022 Volume 2022:15 Pages 3511—3517

DOI https://doi.org/10.2147/DMSO.S371370

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 2

Editor who approved publication: Prof. Dr. Muthuswamy Balasubramanyam

Purpose: Type 2 diabetes mellitus is characterized by the dysregulation of glucose homeostasis and insulin sensitivity, resulting in hyperglycemia. The exploration of a complex regulatory network in host metabolism homeostasis may raise a novel strategy for the prevention of T2D. A variety of metabolites serve as the endogenous ligand of G protein-coupled receptors (GPCR) and play an important role in the pathophysiological process of T2D and insulin resistance, however, the roles of remaining endogenous metabolites in insulin resistance and GPCRs still need to be explored.
Patients and Methods: The effect of LPC (17:0) on hyperglycemia were proved in high fat diet (HFD) mice, and qPCR with Western blot technology was used to verify the downstream targets.
Results: Herein, we found that LPC (17:0) reduced blood glucose and alleviated insulin resistance and related metabolic disorders in high-fat diet induced (HFD) mice through activating GLP-1 and promoting insulin secretion. Further, the LPC (17:0) was found to stimulate intestinal GPR120, GPR35 and CALCR, with potential effect on GLP-1 stimulation.
Conclusion: The above observation revealed LPC (17:0) as an endogenous protective factor with potential role on GPCRs, and it provided theoretical support for the development of LPC (17:0) as a potent drug candidate or health food additive for insulin resistance and hyperglycemia.
Keywords: lysophosphatidylcholine, hyperglycemia, GPR120, GPR35, CALCR